Triple-Receptor Drug Shows Strong Diabetes and Weight-Loss Results
A phase 3 trial found that the experimental weekly drug retatrutide improved blood sugar control and led to average weight loss of up to 15.3% over 40 weeks in people with type 2 diabetes. Retatrutide activates GLP-1, GIP, and glucagon receptors, unlike existing drugs that target one or two of these pathways. HbA1c fell by 1.69 to 1.94 percentage points depending on dose, compared with 0.81 points for placebo.
Retatrutide is an experimental once-weekly injection for type 2 diabetes and obesity. It stimulates GLP-1, GIP, and glucagon receptors, whereas Ozempic acts on GLP-1 and Mounjaro on GLP-1 and GIP. The phase 3 TRANSCEND-T2D-1 trial enrolled adults whose diabetes was not controlled by diet and exercise alone and who were not using diabetes medications.
Across 48 sites in the United States, Mexico, and India, 537 of 930 screened adults were randomly assigned to placebo or 4 mg, 9 mg, or 12 mg retatrutide for 40 weeks. Gastrointestinal side effects were mostly mild to moderate; 2%–5% stopped treatment. No severe hypoglycemia occurred, and two deaths were judged unrelated. Direct comparisons with existing drugs and longer safety data remain unavailable.
If approved, retatrutide could expand options for people with type 2 diabetes and obesity, especially those needing greater glucose or weight control. Its triple-receptor action may appeal where existing GLP-1 or dual-agonist therapies fall short, though gastrointestinal side effects and unknown long-term safety could affect uptake. Wider use may influence prescribing, costs, and access discussions, but actual societal impact will depend on confirmatory trials, direct comparisons, and affordability.